+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Species differences in ciprofibrate induction of hepatic cytochrome P-450 4A1 and peroxisome proliferation

Species differences in ciprofibrate induction of hepatic cytochrome P-450 4A1 and peroxisome proliferation

Journal of Biochemical Toxicology 7(3): 183-191

Six species (CD-1 mouse, Fischer 344 rat, Syrian golden hamster, Duncan-Hartley guinea pig, half-lop rabbit and marmoset monkey) were treated orally with ciprofibrate, a potent oxyisobutyrate hypolipidaemic drug for 14 days. A dose-dependent liver enlargement was observed in the mouse and rat and at the high dose level in the hamster. A marked dose-dependent increase in the 12-hydroxylation of lauric acid was observed in the treated mouse, hamster, rat, and rabbit, associated with a concomitant elevation in the specific content of cytochrome P-450 4A1 apoprotein, determined by an ELISA technique. Similarly, in these responsive species, an increase in mRNA levels coding for cytochrome P450 4A1 was observed. Lauric acid 12-hydroxylation was unchanged in the guinea pig and marmoset after ciprofibrate pretreatment, and cytochrome P-450 4A1 was not detected immunochemically in liver microsomes from these latter species. In the untreated mouse, hamster, rat, and rabbit, the 12-hydroxylation of lauric acid was more extensive than the 11-hydroxylation, whereas in the guinea pig and marmoset the activity ratios were reversed, with 11-hydroxylation predominating. Peroxisomal fatty acid beta-oxidation was markedly induced in the mouse, hamster, rat, and rabbit on treatment at the higher dose level (39-, 3- and 5-fold, respectively) and was slightly increased in the marmoset (2-fold), yet was unchanged in the guinea pig following treatment. In the marmoset the increase in peroxisomal beta-oxidation was 3- to 4-fold at the high dose level; however, the dose levels used in the marmosetr were 20 and 100 mg/kg as opposed to 2 and 20 mg/kg in the other species. The differences in the foregoing hepatic enzyme responses to ciprofibrate between the species examined in our studies indicate a specific pattern of enzyme changes in responsive species. In the responsive species (rat, mouse, hamster, and rabbit), cytochrome P-450 4A1 specific content and related enzyme activity were increased concomitant with elevated peroxisomal beta-oxidation. By contrast, the marmoset and guinea pig lack the coordinate hepatic induction of peroxisomal and microsomal parameters and may be categorized as less responsive species. Accordingly, the rat hepatic responses to peroxisome proliferators cannot confidently be used to predict biological responsed in primates, with obvious implications for the extrapolation of animal data to man.

(PDF emailed within 0-6 h: $19.90)

Accession: 009440970

Download citation: RISBibTeXText

PMID: 1282571

DOI: 10.1002/jbt.2570070308

Related references

Characterization of the hepatic responses to the short-term administration of ciprofibrate in several rat strain. Co-induction of microsomal cytochrome P-450 IVA1 and peroxisome proliferation. Biochemical Pharmacology 40(5): 1083-1094, 1990

Comparative induction of cytochrome P450IVA1 and peroxisome proliferation by ciprofibrate in the rat and marmoset. Archives of Toxicology 65(2): 106-113, 1991

Induction of peroxisome proliferation and hepatic tumors in c57bl 6n mice by ciprofibrate a hypolipidemic compound. British Journal of Cancer 58(1): 46-51, 1988

Induction by ciprofibrate of hepatic peroxisome proliferation in rats pigeons chickens cats and rhesus monkeys. Federation Proceedings 41(5): ABSTRACT 8601, 1982

Influence of purified diets on the induction of cell proliferation by the hepatic tumor promoters 2,2,4,4,5,5-hexachlorobiphenyl and the peroxisome proliferator ciprofibrate. FASEB Journal 17(4-5): Abstract No 711 15, March, 2003

Hepatic zonation of the induction of cytochrome P450 IVA, peroxisomal lipid beta-oxidation enzymes and peroxisome proliferation in rats treated with dehydroepiandrosterone (DHEA). Evidence of distinct zonal and sex-specific differences. Carcinogenesis 18(8): 1491-1498, 1997

Effect of dietary selenium on the induction of altered hepatic foci and hepatic tumors by the peroxisome proliferator ciprofibrate. Nutrition and Cancer 14(3-4): 261-271, 1990

Induction of peroxisome proliferation in rainbow trout exposed to ciprofibrate. Toxicology & Applied Pharmacology 104(3): 476-482, 1990

Species differences in hepatic peroxisome proliferation. Biochemical Society Transactions 13(5): 859-861, 1985

Tissue specificity in the induction of peroxisome proliferation associated polypeptide ppa 80 and peroxisomal beta oxidation in rats by ciprofibrate. Federation Proceedings 44(3): 663, 1985

Difference between species in response to a 3,5-dichloropyridyloxyphenoxy compound: induction of cytochrome P-450 and/or peroxisome proliferation. Food Additives and Contaminants 6 Suppl 1: S41-S55, 1989

Effect of the peroxisome proliferators ciprofibrate and perfluorodecanoic acid on hepatic cell proliferation and toxicity in Sprague-Dawley rats. Carcinogenesis 15(12): 2847-2850, 1994